In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits
- 1 July 1983
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 24 (1) , 31-38
- https://doi.org/10.1128/aac.24.1.31
Abstract
Augmentin (Beecham Laboratories, Bristol, Tenn.), a combination drug consisting of two parts amoxicillin to one part clavulanic acid and a potent beta-lactamase inhibitor, was evaluated in vitro in comparison with ampicillin or amoxicillin or both for its inhibitory and bactericidal activities against selected clinical isolates. Regression analysis was performed and tentative disk diffusion susceptibility breakpoints were determined. A multicenter performance study of the disk diffusion test was conducted with three quality control organisms to determine tentative quality control limits. All methicillin-susceptible staphylococci and Haemophilus influenzae isolates were susceptible to Augmentin, although the minimal inhibitory concentrations for beta-lactamase-producing strains of both groups were, on the average, fourfold higher than those for enzyme-negative strains. Among the Enterobacteriaceae, Augmentin exhibited significantly greater activity than did ampicillin against Klebsiella pneumoniae, Citrobacter diversus, Proteus vulgaris, and about one-third of the Escherichia coli strains tested. Bactericidal activity usually occurred at the minimal inhibitory concentration. There was a slight inoculum concentration effect on the Augmentin minimal inhibitory concentrations. On the basis of regression and error rate-bounded analyses, the suggested interpretive disk diffusion susceptibility breakpoints for Augmentin are: susceptible, greater than or equal to 18 mm; resistant, less than or equal to 13 mm (gram-negative bacilli); and susceptible, greater than or equal to 20 mm (staphylococci and H. influenzae). The use of a beta-lactamase-producing organism, such as E. coli Beecham 1532, is recommended for quality assurance of Augmentin susceptibility testing.This publication has 19 references indexed in Scilit:
- Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acidAntimicrobial Agents and Chemotherapy, 1982
- Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infectionsAntimicrobial Agents and Chemotherapy, 1982
- Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combinationAntimicrobial Agents and Chemotherapy, 1982
- In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillinJournal of Antimicrobial Chemotherapy, 1980
- Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicinAntimicrobial Agents and Chemotherapy, 1980
- Effect of clavulanic acid and amoxycillin formulation against β-lactamase producing Gram-negative bacteria in urinary tract infectionsJournal of Antimicrobial Chemotherapy, 1979
- Effect of Clavulanic Acid on the Minimum Inhibitory Concentration of Benzylpenicillin, Ampicillin, Carbenicillin, or Cephalothin Against Clinical Isolates Resistant to Beta-Lactam AntibioticsAntimicrobial Agents and Chemotherapy, 1979
- Clavulanic Acid, a Novel Inhibitor of β-LactamasesAntimicrobial Agents and Chemotherapy, 1978
- In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillinAntimicrobial Agents and Chemotherapy, 1978
- Susceptibility Tests of Anaerobic Bacteria: Statistical and Clinical ConsiderationsThe Journal of Infectious Diseases, 1974